Catalyst Wire Dossier Catalyst Wire Dossier

Monovalent Inactivated Influenza Vaccine with MF59C.1 (H5N1)

Monovalent MF59-adjuvanted H5N1 influenza vaccine · Novartis Vaccines
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Monovalent Inactivated Influenza Vaccine with MF59C.1 (H5N1), covering 2016-12-01 to 2016-12-01. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules [Phase 3]

See pricing